The acquisition is from Yapan's existing shareholders and is referred to as the "Proposed Transaction." Following the approval, the company is engaged in discussions with Yapan's promoters/shareholders regarding various matters required to complete the transaction.
The final terms of the acquisition, including the acquisition consideration and the effective date of share transfer, have not been finalized. The company committed to making appropriate disclosures with required details under Regulation 30 of SEBI LODR Regulations upon execution of definitive documentation and completion of the transaction.
Yapan Bio Private Limited is described as a Contract Development and Manufacturing Organization (CDMO) that specializes in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics.
The transaction will result in Piramal Pharma's shareholding in Yapan increasing from the current 33.33% to approximately 74.33%, which will consequently make Yapan a subsidiary of Piramal Pharma Limited.
The disclosure was signed by Maneesh Sharma, Company Secretary & Compliance Officer, on August 10, 2026, at 17:49:29 IST.
#PiramalPharma #YapanBio #M&A #SEBIDisclosure #RegulatoryCompliance #CorporateAction